Category Archives: Schering Boceprivir Vertex Telaprevir Morgan Stanley Un

Meanwhile, Vertex had a "Great Day" — at Morgan Stanley’s Global Healthcare "Unplugged" Conference, Yesterday. . . .

Do watch the full-webcast [only about 27 minutes long] — note the fast track Phase III status of Vertex’s Teleprevir — and the truly upbeat assessment of its position, vis-a-vis Schering’s boceprivir. Here’s a Vertex PDF file fact sheet (see page one — center chart).

If the above-Morgan Stanley webcast won’t load — try this link, but you’ll need to sign-in.

Vertex is up another $0.25, on the NYSE, as I type this. That is all.